Otsuka Pharmaceutical

Stories

Otsuka, Ionis ALS drug hits primary Phase 3 endpoint, heads to FDA

As of September 2026: Leads development and commercialization of ulefnersen

FUS-ALS patients have no approved drug targeting the cause of their disease. On September 22, an experimental therapy cleared a key hurdle: a Phase 3 trial showed ulefnersen, an RNA-targeted drug, improved function and survival versus placebo.

Updated Sep 22

IgA nephropathy gains five approved drugs in four years

New Capabilities

As of June 2026: Markets Voyxact, the first FDA-approved APRIL inhibitor for IgAN

For decades, doctors had no drugs specifically approved for IgA nephropathy, a kidney disease that pushes up to half of patients toward kidney failure within ten years of diagnosis. Since December 2021, the FDA has approved five.

Updated Jun 1